Glulisine Pre- and Postmeal

Glucodynamic Response to Pre- and Postmeal Subcutaneous Injection of 0.15 IU/kg HMR1964 Insulin and RHI in Type 1 Diabetic Subjects in an Open, Randomized, Four-way Crossover Study

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00290043

Enrollment

Registered

2006-02-10

Start date

2001-12-31

Completion date

2002-03-31

Last updated

2010-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 1

Keywords

Insulin glulisine, Diabetes mellitus Type 1, Postprandial Period, Pharmacokinetics, Glucodynamics

Brief summary

To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal

Interventions

DRUGInsulin glulisine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Type 1 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026